Literature DB >> 20466624

Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma.

Laura Galán1, Antonio C Sánchez, Blanca Cantos, Mariano Provencio.   

Abstract

Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) accounts for approximately 5% of Hodgkin's lymphoma, presents with early-stage disease and has an indolent course. Treatment is not well established. We present a patient diagnosed with NLPHL and treated with Rituximab second-line therapy after chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20466624     DOI： 10.1007/s12094-010-0521-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  11 in total

1.  Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

Authors:  Marinus H J van Oers; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Randy D Gascoyne; Andrew Jack; Mars Van't Veer; Andrej Vranovsky; Harald Holte; Martine van Glabbeke; Ivana Teodorovic; Cynthia Rozewicz; Anton Hagenbeek
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

2.  Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.

Authors:  Lucia Nogová; Thorsten Reineke; Andreas Josting; Hans K Müller-Hermelink; Hans T Eich; Karolin Behringer; Rolf-Peter Müller; Volker Diehl; Andreas Engert
Journal:  Eur J Haematol Suppl       Date:  2005-07

3.  Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.

Authors:  John D Hainsworth; Sharlene Litchy; Howard A Burris; Daniel C Scullin; Steven W Corso; Denise A Yardley; Lisa Morrissey; F Anthony Greco
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

4.  Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.

Authors:  Bradley C Ekstrand; Jennifer B Lucas; Steven M Horwitz; Zhen Fan; Sheila Breslin; Richard T Hoppe; Yasodha Natkunam; Nancy L Bartlett; Sandra J Horning
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

Review 5.  Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.

Authors:  Lucia Nogová; Thomas Rudiger; Andreas Engert
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2006

Review 6.  The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.

Authors:  Lauren S Maeda; Ranjana H Advani
Journal:  Curr Opin Oncol       Date:  2009-09       Impact factor: 3.645

7.  Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.

Authors:  Pierre Feugier; Eric Labouyrie; Malika Djeridane; Arash Jenabian; Viviane Dubruille; Christian Berthou; Christiane Ghandour; Bernard Desablens; Yasmine Chaït; Philippe Casassus; Vincent Delwail; Norbert Ifrah; Annick Le Mevel; Thierry Lamy; Josette Brière; Pierre Colonna; Jean-Marie Andrieu
Journal:  Blood       Date:  2004-07-01       Impact factor: 22.113

8.  Rituximab in lymphocyte-predominant Hodgkin disease.

Authors:  Hatem A Azim; Giancarlo Pruneri; Emilia Cocorocchio; Saverio Cinieri; Paola R Raviele; Simona Bassi; Lorenzo Preda; Giovanni Martinelli; Fedro A Peccatori
Journal:  Oncology       Date:  2008-11-24       Impact factor: 2.935

9.  Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

Authors:  Holger Schulz; Ute Rehwald; Franck Morschhauser; Thomas Elter; Christoph Driessen; Thomas Rüdiger; Peter Borchmann; Roland Schnell; Volker Diehl; Andreas Engert; Marcel Reiser
Journal:  Blood       Date:  2007-10-15       Impact factor: 22.113

10.  Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.

Authors:  Ute Rehwald; Holger Schulz; Marcel Reiser; Markus Sieber; Jan Oliver Staak; Franck Morschhauser; Christoph Driessen; Thomas Rudiger; Konrad Muller-Hermelink; Volker Diehl; Andreas Engert
Journal:  Blood       Date:  2003-01-15       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.